Acesso livre
Acesso livre

Alergia e Imunologia

Encefalite autoimune mediada por anticorpos: uma abordagem prática.

9 Ago, 2021 | 11:08h

Antibody-mediated autoimmune encephalitis: A practical approach – Cleveland Clinic Journal of Medicine

Variantes do SARS-CoV-2 em pacientes imunossuprimidos.

5 Ago, 2021 | 11:58h

SARS-CoV-2 Variants in Patients with Immunosuppression – New England Journal of Medicine

 

Comentário no Twitter

 

Estudo randomizado | Combinação de anticorpos REGEN-COV subcutâneos evitou infecção sintomática por Covid-19 em contactantes de pessoas infectadas.

5 Ago, 2021 | 11:57h

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 – New England Journal of Medicine

Conteúdos relacionados:

RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease).

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

 

Comentário no Twitter

 

Estudo de coorte | Seguimento de 6 meses da síndrome inflamatória multissistêmica em crianças.

3 Ago, 2021 | 11:32h

Six Month Follow-up of Patients With Multisystem Inflammatory Syndrome in Children – Pediatrics (PDF)

Marcador sanguíneo (anticorpos neutralizantes) prediz quem irá desenvolver ‘breakthrough infection’ (infecção em indivíduos vacinados).

3 Ago, 2021 | 11:29h

A blood marker predicts who gets ‘breakthrough’ COVID – Nature

Conteúdos relacionados:

A correlate of protection for SARS-CoV-2 vaccines is urgently needed – “Recent studies suggest that neutralizing antibodies could serve as a correlate of protection for vaccines against SARS-CoV-2 in humans”.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

Covid-19 breakthrough infections in vaccinated health care workers.

Recomendações da ACOG e da SMFM para a vacinação contra COVID-19 em gestantes – “ACOG encoraja seus membros a recomendar enfaticamente a vacinação para suas pacientes.”

2 Ago, 2021 | 19:18h

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM)

Leituras adicionais:

Practice Advisory: COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care

COVID-19 Vaccines and Pregnancy: Conversation Guide for Clinicians

Comentários:

Obstetrician groups recommend COVID vaccine during pregnancy – Associated Press

Statements By Obstetrics Societies Strongly Advise Covid-19 Vaccinations For Pregnant Women – Forbes

 

Comentário no Twitter

 

Opinião | Gestantes devem se vacinar contra COVID? As evidências mostram que é seguro e eficaz.

2 Ago, 2021 | 19:16h

Should pregnant women have a COVID vaccine? The evidence says it’s safe and effective – The Conversation

Diretriz rápida NICE COVID-19 | Trombocitopenia trombótica imune induzida por vacina.

2 Ago, 2021 | 18:37h

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis – National Institute for Health and Care Excellence

Comunicado de imprensa: NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination – National Institute for Health and Care Excellence

Conteúdo relacionado: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

Análise das evidências | Piperacilina-tazobactam é segura em pacientes alérgicos à penicilina?

2 Ago, 2021 | 17:20h

Is piperacillin-tazobactam safe in patients with penicillin allergy? – PulmCrit

Casos muito raros da síndrome de trombose com trombocitopenia (STT) após vacina AstraZeneca – A estimativa de STT após a primeira dose foi de 8,1 por milhão de vacinas; depois da segunda dose, a estimativa foi de 2,3 por milhão de vacinas.

2 Ago, 2021 | 17:05h

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis – The Lancet

Conteúdos relacionados:

WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).

AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

Case series: therapeutic plasma exchange in 3 patients with vaccine-induced immune thrombotic thrombocytopenia.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations.

Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.

Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.

Case series: Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia.

Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

[Preprint] Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine – Overall risk is 1 in 139,000; for age 65 and over, about 1 in 1,000,000; for age under 55, between 1 in 20,000 to 60,000.

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination

Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Editorial: SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – “The very low prevalence of this complication of vaccination, however severe, relative to the benefits of preventing Covid-19 must be emphasized”

Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.